In NSCLC BMs, tyrosine kinase inhibitors (erlotinib, gefitinib) have demonstrated good BBB penetration, and ALK inhibitors and ICIs are also available options for treatment [287]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.